Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Southern Cross Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (263)
Cancellation by sponsor (205)
Prescription medicine registration (22)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2026 (6)
2025 (5)
2024 (16)
2023 (30)
2022 (102)
2021 (29)
2020 (50)
2019 (59)
2018 (35)
2017 (50)
2016 (22)
2015 (17)
2014 (9)
2013 (11)
2012 (19)
2011 (9)
2010 (9)
2009 (13)
2008 (3)
2007 (1)
2003 (1)

Search

Sponsor content

496 result(s) found, displaying 401 to 410

MODAFINIL AN modafinil 100 mg tablets blister pack Cancelled under Section 30(1)(c) of the Act

13 June 2018

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PHARMACY CHOICE COLD SORE ONE DOSE TREATMENT famciclovir 500mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

14 May 2018

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
TIBOLONE RMB, TIBOLONE SANDOZ, TIBOLONE SCP (Southern Cross Pharma Pty Ltd)

20 March 2018

Prescription medicine registration

Active ingredients: tibolone.
LEFLUNOMIDE GENERICHEALTH (Southern Cross Pharma Pty Ltd)

1 February 2018

Prescription medicine registration

Active ingredients: leflunomide.
MOXONIDINE SCP, MOXONIDINE TLB, APO-MOXONIDINE, MOXONIDINE RMB, MOXONIDINE AJS, MOXONIDINE SANDOZ (Southern Cross Pharma Pty Ltd)

15 December 2017

Prescription medicine registration

Active ingredients: moxonidine.
AusPAR: Ephedrine Hydrochloride

2 November 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ephedrine hydrochloride
LEFLUNOMIDE GENERICHEALTH leflunomide 20mg tablet bottle (210921)

2 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LEFLUNOMIDE GENERICHEALTH leflunomide 20mg tablet bottle.
LEFLUNOMIDE SANDOZ leflunomide 10mg tablet bottle (210905)

2 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LEFLUNOMIDE SANDOZ leflunomide 10mg tablet bottle.
LEFLUNOMIDE SANDOZ leflunomide 20mg tablet bottle (210906)

2 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LEFLUNOMIDE SANDOZ leflunomide 20mg tablet bottle.
LEFLUNOMIDE GENERICHEALTH leflunomide 10mg tablet bottle (210920)

2 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LEFLUNOMIDE GENERICHEALTH leflunomide 10mg tablet bottle.

Pages

First page
Previous page
…
Page 37
Page 38
Page 39
Page 40
Current page 41
Page 42
Page 43
Page 44
Page 45
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.